Medications

Farxiga approved to reduce risk for CKD progression

(HealthDay)—Farxiga (dapagliflozin) oral tablets are now approved for adults with chronic kidney disease at risk for disease progression, the U.S. Food and Drug Administration announced Friday.

page 23 from 40